
Hybrid Sr. Clinical Trial Manager
Bridgebio · San Francisco, CA/Hybrid, Estados Unidos De América · Hybrid
Supera tus entrevistas tecnológicas con sesiones de prueba y tutores expertos de las mejores empresas.
Patrocinado por Exponent
Ideas clave sobre libros en 15 minutos. ¡Ahorre un 40% ahora!
Patrocinado por Blinkist
Adquiera conocimientos en las mejores universidades en línea. ¡Haga avanzar su carrera hoy mismo!
Patrocinado por Coursera
Bridgebio · San Francisco, CA/Hybrid, Estados Unidos De América · Hybrid
Bridgebio · San Francisco, CA/Hybrid, Estados Unidos De América · Hybrid
Bridgebio · San Francisco, CA/Hybrid, Estados Unidos De América · Hybrid
Bridgebio · San Francisco, CA/Hybrid, Estados Unidos De América · Hybrid
Bridgebio · San Francisco, CA/Hybrid, Estados Unidos De América · Hybrid
Bridgebio · San Francisco, CA/Hybrid, Estados Unidos De América · Hybrid
Bridgebio · San Francisco, CA/Hybrid, Estados Unidos De América · Hybrid
Bridgebio · San Francisco, CA/Hybrid, Estados Unidos De América · Hybrid
Bridgebio · San Francisco, CA/Hybrid, Estados Unidos De América · Hybrid
Bridgebio · San Francisco, CA/Hybrid, Estados Unidos De América · Hybrid
Bridgebio · San Francisco, CA/Hybrid, Estados Unidos De América · Hybrid
Bridgebio · San Francisco, CA/Hybrid, Estados Unidos De América · Hybrid
Bridgebio · San Francisco, CA/Hybrid, Estados Unidos De América · Hybrid
Solicitar ahora
Exponent – Supera tus entrevistas tecnológicas con sesiones de prueba y tutores expertos de las mejores empresas.
Patrocinado por ExponentEidos Therapeutics, an affiliate of BridgeBio Pharma, is a Phase 3 developmental-stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. We seek to treat this well-defined family of diseases at their collective source by stabilizing TTR. Our investigational product, acoramidis (AG10), is an orally administered small molecule designed to potently stabilize TTR, a potentially best-in-class treatment aiming to halt the progression of ATTR diseases.
BridgeBio is a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. We bridge the gap between remarkable advancements in genetic science in academic institutions and the delivery of meaningful medicines to patients. Founded in 2015, the company has built a portfolio of 30+ drug development programs ranging from preclinical to late-stage development in multiple therapeutic areas including genetic dermatology, precision oncology, cardiology, endocrinology, neurology, pulmonology, and renal disease, with two approved drugs.
Our focus on scientific excellence and rapid execution aims to translate today’s discoveries into tomorrow’s medicines. We have U.S. offices in San Francisco, Palo Alto, and Raleigh, with small satellites in other parts of the country. We also have international offices in Montreal, Canada, and Zurich, Switzerland, and are expanding across Europe.
To learn more about our story and company culture, visit us at eidostx.com/ | https://bridgebio.com
The Senior Clinical Trial Manager is responsible for the execution and management of assigned clinical studies while ensuring Good Clinical Practices (GCP) Compliance, high study quality, and timely completion. This position is responsible for assisting in meeting functional, organizational, and corporate goals for acoramidis (AG10) by providing successful management of clinical study teams and clinical trials.
No matter your role at BridgeBio, successful team members are: